Trial Profile
An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients With Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ABI-RE
- 22 Mar 2017 Status changed from recruiting to discontinued.
- 29 Jan 2016 New trial record